RAIN THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)

Item 7.01 Regulation FD Disclosure.

On November 4, 2022, Rain Therapeutics Inc. (the "Company") made available an updated corporate presentation. Also on November 4, 2022, the Company issued a press release announcing interim analysis of its Phase 2 basket trial of milademetan for mouse double minute 2 (MDM2)-amplified advanced solid tumors (MANTRA-2).

The corporate presentation and press release are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, which are furnished under Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

© Edgar Online, source Glimpses